Thymosin Beta-4

Thymosin Beta-4 (Tβ4), also known by the WHO International Nonproprietary Name "timbetasin," is a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene on the human X chromosome. Its sequence is Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser, giving it a molecular formula of C212H350N56O78S and an average molecular weight of approximately 4,921 Daltons (PubChem CID 45382195). It is one of the most abundant intracellular peptides in mammalian cells and is found in nearly all tissue types, with particularly high concentrations in platelets, white blood cells, and wound-healing tissue.

At Verified Peptides, we source and profile research-grade Thymosin Beta-4 as a distinct compound from TB-500, a shorter synthetic peptide that is sometimes marketed as containing the "active fragment" region of Tβ4. Full-length Thymosin Beta-4, the compound this page describes, is the complete 43-amino-acid endogenous sequence, not a truncated analog. This distinction matters for researchers comparing published data, since studies conducted on the full-length peptide and studies conducted on shorter fragments are not automatically interchangeable.

Thymosin Beta-4 was first characterized in the early 1980s during research into thymic extracts, and its principal biochemical role was subsequently identified as the primary G-actin-sequestering protein in the cytoplasm of most eukaryotic cells. Beyond this intracellular structural function, Tβ4 is released extracellularly during tissue injury and inflammation, where it exhibits what researchers describe as "protein moonlighting" — a distinct set of signaling functions unrelated to its actin-binding role, thought to involve interactions with cell-surface receptors. This dual intracellular/extracellular behavior is central to why the peptide has drawn sustained research interest across wound healing, cardiovascular, and inflammation-related fields.

At Verified Peptides, we track the published clinical and preclinical research on Thymosin Beta-4 closely because its evidence base is genuinely mixed rather than uniformly positive, and we believe researchers deserve that nuance rather than a simplified success narrative. The most clinically advanced Tβ4 research program has been RGN-259, a topical 0.1% Thymosin Beta-4 ophthalmic solution developed for dry eye disease and neurotrophic keratopathy. A Phase 2 randomized, double-masked, placebo-controlled trial in patients with severe dry eye disease (Cornea, 2015; PMID 25826322) found statistically significant improvements in both signs and symptoms compared with vehicle control over a 28-day treatment period with a 28-day follow-up.

A subsequent Phase III randomized, placebo-controlled, double-masked trial of 0.1% RGN-259 in patients with Stage 2–3 neurotrophic keratopathy (International Journal of Molecular Sciences, 2022; PMID 36613994; N=18) produced a genuinely mixed result that is worth describing precisely rather than rounding up. The trial's primary endpoint at Day 29 narrowly missed statistical significance (6 of 10 RGN-259-treated subjects achieved complete healing versus 1 of 8 placebo subjects, p=0.0656), while a secondary Mackie disease-stage classification measure at Day 43 did reach significance (70% of treated subjects shifted to Stage 1 or complete healing versus 25% of placebo, p=0.0467), as did a sustained-healing measure two weeks after treatment ended (p=0.0359). A separate, larger Phase 3 trial in neurotrophic keratitis (publicly referred to as SEER-3, conducted by HLB Therapeutics) has been reported by the company to have missed its primary endpoint, a result attributed to an unexpectedly strong placebo response in the control arm rather than to a lack of treated-group improvement. We are citing this honestly as a company-reported, topline result rather than as a peer-reviewed finding, since we have not located a peer-reviewed publication of that specific trial.

Separately from the ophthalmic research program, Phase 2 trials of Thymosin Beta-4 administered for dermal wound healing — including chronic pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds (a registered trial is available at ClinicalTrials.gov under identifier NCT00382174) — reported accelerated rates of wound repair compared with standard care, with proposed mechanisms including enhanced keratinocyte migration, increased dermal cellularity, accelerated granulation tissue formation, and increased collagen deposition and angiogenesis at the wound site. A related Phase 2 trial examined Tβ4 for corneal wound healing (ClinicalTrials.gov identifier NCT00598871). A separate review publication (PMID 27450738) summarizes the broader body of dermal-healing research on the peptide.

No Thymosin Beta-4 formulation — ophthalmic, topical, or injectable — has received FDA approval for any indication as of this writing, and no New Drug Application specific to Tβ4 or RGN-259 has been approved. At Verified Peptides, we sell research-grade Thymosin Beta-4 as an entirely separate product from any pharmaceutical candidate in clinical development, intended exclusively for laboratory and research use, not for human or animal treatment.

Thymosin Beta-4 is one of the most abundant peptides in the human body by intracellular concentration, yet most people have never heard of it — a reflection of how much foundational cell-biology research happens far from public attention. Its most cited research role, buffering the pool of free G-actin inside virtually every nucleated cell, means it is technically present and functionally active in essentially all human tissue, not concentrated in one organ system the way many hormones are.

A frequently overlooked regulatory fact is that Thymosin Beta-4 is a substance banned in competitive sports by the World Anti-Doping Agency (WADA), classified alongside other growth factors and peptides prohibited for their potential to enhance soft-tissue recovery. This status has surfaced in real doping investigations, including cases connected to Australian rugby league and AFL football involving the peptide program run by sports scientist Stephen Dank in the early 2010s — making Tβ4 one of the few compounds in this build batch with a documented anti-doping enforcement history rather than only a pharmaceutical regulatory profile.

Beyond wound healing, researchers have investigated Tβ4 in several less publicized directions. Preclinical studies have examined its potential in neuroprotection, including models of traumatic brain injury and stroke, where extracellular Tβ4 signaling has been associated with reduced inflammatory injury and improved functional recovery in animals. Separately, anti-fibrotic research has studied Tβ4's effect on scar-tissue formation in cardiac, renal, and hepatic injury models, exploring whether its actin-regulatory and anti-inflammatory activity could reduce pathological fibrosis. Veterinary and equine research has also used Tβ4 (and shorter fragments derived from it) in tendon and soft-tissue injury studies in horses, a use case that predates much of the human clinical research and has its own body of published literature.

Finally, Thymosin Beta-4 is synthesized commercially via solid-phase peptide synthesis rather than extracted from biological tissue, which is standard practice for a 43-residue peptide of this kind and allows for consistent, scalable, high-purity production without the batch variability of tissue-derived material.

At Verified Peptides, we require third-party HPLC (high-performance liquid chromatography) purity testing and mass spectrometry identity confirmation for every batch of research-grade Thymosin Beta-4 we offer, and we make the resulting Certificate of Analysis (COA) available for each lot. Because Tβ4 is a relatively large, 43-residue peptide, synthesis and purification are more technically demanding than for many shorter research peptides, and batch-to-batch purity verification is correspondingly important for anyone relying on consistent experimental results.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified before it is offered for sale — we do not rely solely on a supplier's own internal testing. Researchers should always request and review the specific COA for the lot they receive, checking purity percentage, confirmed molecular identity via mass spectrometry, and endotoxin/microbial testing where applicable, rather than assuming uniform quality across suppliers or even across different lots from the same supplier.

Because Thymosin Beta-4 research spans such a wide range of experimental contexts — cell-culture actin-dynamics studies, in vivo wound-healing models, and cardiovascular or fibrosis research — purity and identity verification take on outsized importance for reproducibility. A peptide sample with unconfirmed identity or degraded purity can meaningfully confound actin-binding assays or in vivo outcome measures, making third-party verification a baseline requirement rather than an optional add-on for serious research use.

Lyophilized (freeze-dried) Thymosin Beta-4 is stable when stored at -20°C, and researchers can generally expect the unreconstituted peptide to maintain integrity for extended periods under these conditions, protected from light and moisture. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted with bacteriostatic water or an appropriate sterile diluent, Thymosin Beta-4 solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation, as reconstituted peptide solutions are generally less stable over time than the lyophilized form and are more susceptible to degradation, microbial contamination, and loss of structural integrity with repeated freeze-thaw cycles. Researchers should avoid repeated freeze-thaw cycling of reconstituted material and should aliquot solutions where possible to minimize the number of times any single vial is thawed.

As with all peptides of this size and complexity, exposure to excessive heat, direct light, or extended room-temperature storage accelerates degradation and can compromise the structural and functional integrity relevant to research applications. Following the specific storage guidance provided with each lot's documentation remains the most reliable way to preserve a sample's research validity.